[
  {
    "ts": null,
    "headline": "Bristol Myers Squibb Co. stock underperforms Monday when compared to competitors",
    "summary": "Bristol Myers Squibb Co. stock underperforms Monday when compared to competitors",
    "url": "https://finnhub.io/api/news?id=40bb0954f07c7e32f690ad11c7fb228204012c63df461c5a2fb6bb41477ff2d2",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753115940,
      "headline": "Bristol Myers Squibb Co. stock underperforms Monday when compared to competitors",
      "id": 136049839,
      "image": "",
      "related": "BMY",
      "source": "MarketWatch",
      "summary": "Bristol Myers Squibb Co. stock underperforms Monday when compared to competitors",
      "url": "https://finnhub.io/api/news?id=40bb0954f07c7e32f690ad11c7fb228204012c63df461c5a2fb6bb41477ff2d2"
    }
  },
  {
    "ts": null,
    "headline": "EdgeOne Medical Announces Appointment of Michael Denzer as VP, Client Relations to Further Elevate Product Innovation and Client Partnerships",
    "summary": "WHEELING, Ill., July 21, 2025--EdgeOne Medical, a professional service organization focused on device development service for combination products in the bio-pharmaceutical industry is pleased to announce the appointment of Mr. Michael Denzer as Vice President of Client Relations.",
    "url": "https://finnhub.io/api/news?id=b50b912444b416c14c990d86bc9b3c2b1fd97fca3b2a0ef8d8b31341a2993dbf",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753110000,
      "headline": "EdgeOne Medical Announces Appointment of Michael Denzer as VP, Client Relations to Further Elevate Product Innovation and Client Partnerships",
      "id": 136025614,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "WHEELING, Ill., July 21, 2025--EdgeOne Medical, a professional service organization focused on device development service for combination products in the bio-pharmaceutical industry is pleased to announce the appointment of Mr. Michael Denzer as Vice President of Client Relations.",
      "url": "https://finnhub.io/api/news?id=b50b912444b416c14c990d86bc9b3c2b1fd97fca3b2a0ef8d8b31341a2993dbf"
    }
  },
  {
    "ts": null,
    "headline": "Betting Big on Cancer: 3 Oncology Stocks Set to Surge in 2025",
    "summary": "J&J, Novartis and Allogene Therapeutics are making bold oncology moves as demand surges for next-generation cancer therapies.",
    "url": "https://finnhub.io/api/news?id=b68b0e8b783d65219841418cceddcf5f3bd8e35ed1c4cc6bf5878cb8d8027ef6",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753105260,
      "headline": "Betting Big on Cancer: 3 Oncology Stocks Set to Surge in 2025",
      "id": 136025389,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "J&J, Novartis and Allogene Therapeutics are making bold oncology moves as demand surges for next-generation cancer therapies.",
      "url": "https://finnhub.io/api/news?id=b68b0e8b783d65219841418cceddcf5f3bd8e35ed1c4cc6bf5878cb8d8027ef6"
    }
  },
  {
    "ts": null,
    "headline": "3 Top-Ranked Dividend Stocks: A Smarter Way to Boost Your Retirement Income",
    "summary": "The traditional ways to plan for your retirement may mean income can no longer cover expenses post-employment. But what if there was another option that could provide a steady, reliable source of income in your nest egg years?",
    "url": "https://finnhub.io/api/news?id=66acdca08df2b87ab4d9da7b5bcaadaba53d0377ff18c46eeb4fbf06d3694a73",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753103403,
      "headline": "3 Top-Ranked Dividend Stocks: A Smarter Way to Boost Your Retirement Income",
      "id": 136025717,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "The traditional ways to plan for your retirement may mean income can no longer cover expenses post-employment. But what if there was another option that could provide a steady, reliable source of income in your nest egg years?",
      "url": "https://finnhub.io/api/news?id=66acdca08df2b87ab4d9da7b5bcaadaba53d0377ff18c46eeb4fbf06d3694a73"
    }
  },
  {
    "ts": null,
    "headline": "Bristol-Myers Squibb Company (BMY): All Or Nothing With A Breakthrough Drug, Says Jim Cramer",
    "summary": "We recently published 8 Stocks That Jim Cramer Recently Talked About. Bristol-Myers Squibb Company (NYSE:BMY) is one of the stocks Jim Cramer recently discussed. Bristol-Myers Squibb Company (NYSE:BMY) is one of the largest and most well-known American pharmaceutical companies. It has long been one of Cramer’s favorite stocks as the CNBC TV host has been […]",
    "url": "https://finnhub.io/api/news?id=b2d0c3fd634ed3b13d8591a1ea5198788d2904643653e14c19bedd5fb424a376",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753102471,
      "headline": "Bristol-Myers Squibb Company (BMY): All Or Nothing With A Breakthrough Drug, Says Jim Cramer",
      "id": 136025718,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "We recently published 8 Stocks That Jim Cramer Recently Talked About. Bristol-Myers Squibb Company (NYSE:BMY) is one of the stocks Jim Cramer recently discussed. Bristol-Myers Squibb Company (NYSE:BMY) is one of the largest and most well-known American pharmaceutical companies. It has long been one of Cramer’s favorite stocks as the CNBC TV host has been […]",
      "url": "https://finnhub.io/api/news?id=b2d0c3fd634ed3b13d8591a1ea5198788d2904643653e14c19bedd5fb424a376"
    }
  },
  {
    "ts": null,
    "headline": "Bristol Myers Squibb’s Supplemental New Drug Application (sNDA) for Sotyktu (deucravacitinib) for the Treatment of Adults with Active Psoriatic Arthritis Accepted for Review Across Four Regions Globally",
    "summary": "PRINCETON, N.J., July 21, 2025--BMS's Supplemental New Drug Application for Sotyktu for the Treatment of Adults with Active Psoriatic Arthritis Accepted for Review...",
    "url": "https://finnhub.io/api/news?id=5f6388452de712225872e78763ef12da7070b587edb79a823c7d88ab1d466873",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753095540,
      "headline": "Bristol Myers Squibb’s Supplemental New Drug Application (sNDA) for Sotyktu (deucravacitinib) for the Treatment of Adults with Active Psoriatic Arthritis Accepted for Review Across Four Regions Globally",
      "id": 136025719,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "PRINCETON, N.J., July 21, 2025--BMS's Supplemental New Drug Application for Sotyktu for the Treatment of Adults with Active Psoriatic Arthritis Accepted for Review...",
      "url": "https://finnhub.io/api/news?id=5f6388452de712225872e78763ef12da7070b587edb79a823c7d88ab1d466873"
    }
  },
  {
    "ts": null,
    "headline": "BMS’ Phase III trial of Reblozyl misses primary endpoint",
    "summary": "Despite not meeting the endpoint, subjects have experienced a meaningful improvement in RBC transfusion independence.",
    "url": "https://finnhub.io/api/news?id=73ee13c0cfcbdc9b6785efc04b8cfbaf6fca36fbd37350c96b99b550f3c613b0",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753090285,
      "headline": "BMS’ Phase III trial of Reblozyl misses primary endpoint",
      "id": 136025720,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "Despite not meeting the endpoint, subjects have experienced a meaningful improvement in RBC transfusion independence.",
      "url": "https://finnhub.io/api/news?id=73ee13c0cfcbdc9b6785efc04b8cfbaf6fca36fbd37350c96b99b550f3c613b0"
    }
  },
  {
    "ts": null,
    "headline": "Bristol Myers Says FDA to Review Sotyktu for Active Psoriatic Arthritis",
    "summary": "Bristol Myers Says FDA to Review Sotyktu for Active Psoriatic Arthritis",
    "url": "https://finnhub.io/api/news?id=c500808577615c599d63c2a5eaee50a9ba622a784e5eb43b3d607f589a67d7d8",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753082040,
      "headline": "Bristol Myers Says FDA to Review Sotyktu for Active Psoriatic Arthritis",
      "id": 136049840,
      "image": "",
      "related": "BMY",
      "source": "MarketWatch",
      "summary": "Bristol Myers Says FDA to Review Sotyktu for Active Psoriatic Arthritis",
      "url": "https://finnhub.io/api/news?id=c500808577615c599d63c2a5eaee50a9ba622a784e5eb43b3d607f589a67d7d8"
    }
  }
]